PENGARUH PEMBERIAN KOMBINASI OBAT DUTASTERIDE DAN TAMSULOSIN TERHADAP KADAR PSA (PROSTATE SPECIFIC ANTIGEN) PADA PASIEN BPH (BENIGN PROSTATIC HYPERPLASIA) DI RSUD PROVINSI NUSA TENGGARA BARAT
DOI:
https://doi.org/10.29303/jku.v9i1.405Keywords:
BPH, PSA, dutasteride, tamsulosinAbstract
Latar belakang: Benign Prostatic Hyperplasia (BPH) merupakan tumor jinak yang biasa dijumpai pada 1 dari 3 pria yang berusia lebih dari 50 tahun. Sedangkan Prostate Specific Antigen (PSA) adalah protein yang dihasilkan oleh kelenjar prostat yang bersifat organ spesifik dan diperiksa pada semua pasien BPH untuk mengetahui perjalanan penyakit BPH. Penggunaan obat dutasteride pada BPH dapat menghambat perubahan testosteron menjadi dihidrotestosteron serta dapat menekan pertumbuhan prostat karena obat ini termasuk dalam golongan inhibitor 5 alfa reduktase. Tamsulosin termasuk dalam golongan obat antagonis reseptor alfa 1 yang dapat merelaksasikan tonus otot polos kelenjar prostat dan leher buli-buli.
Metode: Penelitian ini menggunakan desain penelitian komparatif dengan pendekatan eksperimental dan metode pengambilan data dengan pengukuran berulang (pre test – post test field trial). Pengambilan data dilakukan di Instalasi Rawat Jalan Poliklinik Bedah Urologi dan Instalasi Rekam Medis RSUD Provinsi NTB pada periode waktu Oktober 2019 sampai dengan Desember 2019.
Hasil: Dari 32 responden yang dilakukan pemeriksaan PSA awal dan akhir didapatkan rata-rata kadar PSA awal terbanyak pada kelompok <4 ng/ml dan rata-rata kadar PSA akhir terbanyak pada kelompok <4 ng/ml. Rata-rata responden berasal dari kelompok usia 61-69 tahun. Berdasarkan uji hipotesis menggunakan uji paired sample T test diperoleh nilai p = 0,035 (p < 0,05) menunjukkan terdapat perubahan kadar PSA pada pasien BPH yang sudah diberi kombinasi obat dutasteride dan tamsulosin.
Kesimpulan: Terdapat perubahan kadar PSA pada pasien BPH yang sudah diberi terapi menggunakan kombinasi obat dutasteride dan tamsulosin di RSUD Provinsi Nusa Tenggara Barat.
References
2. Mochtar, CA., Umbas, R., Soebadi, DM., Rasyid, N., Noegroho, BS., Poernomo, BB., Tjahjodjati., Danarto, HR., Wijanarko, S., Warli, SM., Hamid, ARAH. 2015. Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia/BPH).
3. Egan, K. 2016. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms. Urologic Clinics of North America, 43(3), pp: 289-297.
4. Chughtai, B., Forde, J., Thomas, D., Laor, L., Hossack, T., Woo, H., Te, A. and Kaplan, S. 2016. Benign Prostatic Hyperplasia. Nature Reviews Disease Primers, 2(1). [online] Available at: https://doi.org/10.1038/nrdp.2016.31
5. Woodard, TJ., Manigault, KR., McBurrows, NN., Wray, TL., Woodard, LM. 2016. Management of Benign Prostatic Hyperplasia in Older Adults. The Consultant Pharmacist, 31(8), pp: 412-423
6. Ito, K., Miyakubo, M., Sekine, Y., Koike, H., Matsui, H., Shibata, Y. and Suzuki, K. 2012. Diagnostic Significance of Pro-PSA and Prostate Dimension-Adjusted PSA-Related Indices in Men with Total PSA in The 2.0–10.0 ng/mL Range. World Journal of Urology, 31(2), pp: 305-311.
7. Pron, G. 2015. Prostate-Specific Antigen (PSA)–Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 15(10), pp: 1-64
8. Tawfik, A. 2015. Prostate-Specific Antigen (PSA)–Based Population Screening for Prostate Cancer: An Economic Analysis. Ontario Health Technology Assessment Series, 15(11), pp: 1-37
9. Khodjojo KZ. 1999. Perbandingan Hasil Pemeriksaan Klinis Preoperatif dan Patologi Anatomi pada Penderita Pembesaran Prostat Jinak, Karya Akhir, Makassar, pp: 1-11.
10. Amalia, M. Rizki. 2007. Faktor-Faktor Risiko Terjadinya Pembesaran Prostat Jinak (Studi kasus di RS dr. Kariadi, RS Roemani dan RSI Sultan Agung Semarang), Tesis, Program Studi Magister Epidemiologi, Program Pasca Sarjana Universitas Diponegoro Semarang.
11. Meigs, JB., et al. 2001. Risk Factors for Clinical Benign Prostatic Hyperplasia in a Community-Based Population of Healthy Aging Men. Journal of Clinical Epidemiology Vol. 54, Issue 9, pp: 935-44.
12. Juhee H, et al. 2006. Risk Factors for Benign Prostatic Hyperplasia in South Korean Men. Urologia Internationalis, pp:11-19.
13. Sarwar, S., Adil, M., Nyamath, P. and Ishaq, M. 2017. Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus. Prostate Cancer, pp: 1-7.
14. SP, I. 2013. The Efficiency of the Serum Prostate Specific Antigen Levels in Diagnosing Prostatic Enlargements. Journal Of Clinical And Diagnostic Research.
15. Haid M, Rabin D, King KM. 1994. Digital Rectal Examination, Serum Prostatic Specific Antigen and Prostatic Ultrasound: How Effective is The Diagnostic Triad ?. J Surg Oncol, pp: 32-38.
16. Babain RJ, Camps JL. 1991. The Role of Prostatic Specific Antigen as Part of The Diagnostic Triad and as A Guide When to Perform A Biopsy Cancer. 68(9): 2060-3
17. Dawson, C. and Whitfield, H. 1996. ABC of Urology: Bladder Outflow Obstruction. BMJ, 312(7033), pp: 767-770.
18. US Food and Drugs Administration. 2008. Avodart Prescribing Information. [online] Available at: https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021319s015lbl.pdf&ved=2ahUKEwjrz4KDjIbnAhUw6nMBHRm4AwsQFjALegQIBBAB&usg=AOvVaw2pf0a4unufDHfQ7n27fZPq [Accessed 11 Jan. 2020]
19. Pandanwangi, S. T. W., Fauzia, RR. 2018. Pengaruh Terapi Tamsulosin dengan Dutasteride terhadap Kualitas Hidup Pasien Benign Prostate Hyperplasia di RSUD Gunung Jati Cirebon. Farmasains 5(2), pp: 41-45.
20. Amirudin, Pandanwangi, S. T. W. 2016. Kajian Perbandingan Efektivitas Tamsulosin, Dutasteride dan Kombinasinya Pada Pasien BPH di RSUD Gunung Jati Cirebon. Farmasains 5(2), pp: 90-99.
21. Lagiou, A., Samoli, E., Georgila, C., Minaki, P., Barbouni, A., Tzonou, A., Trichopoulos, D. and Lagiou, P. 2008. Occupational Physical Activity in Relation with Prostate Cancer and Benign Prostatic Hyperplasia. European Journal of Cancer Prevention, 17(4), pp: 336-339.
22. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F,Stampfer MJ. 1995. A Prospective Study of Plasma Hormone Levels, Nonhormonal Factors, and Development of Benign Prostatic Hyperplasia. Prostate, pp: 40–49.
23. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. 1996. Prospective Study of Sex Hormone Levels and Risk of Prostate Cancer. J National Cancer Inst, pp: 1118–1126.
24. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami H-O. 1997. Insulin-Like Growth Factor 1 in Relation to Prostate Cancer And Benign Prostatic Hyperplasia. Brit J Cancer 76, pp: 1115–1118.
25. Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, et al. 2002. Insulin-Like Growth Factors and Risk of Benign Prostatic Hyperplasia. Prostate52, pp: 98–105.
26. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. 2003. A Low-Fat Diet and/or Strenuous Exercise Alters The IGF Axis in Vivo and Reduces Prostate Tumor Cell Growth in Vitro. Prostate 56, pp: 201–206.
27. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. 2003. Insulin-Like Growth Factor I (IGF-I) And IGF Binding Protein-1 Modulate Prostate Cancer Cell Growth and Apoptosis: Possible Mediators for The Effects of Diet and Exerciseon Cancer Cell Survival. Endocrinology 144, pp: 2319–2324.
28. Daly W, Seegers CA, Rubin DA, Dobridge JD, Hackney AC. 2005. Relationship between Stress Hormones and Testosterone with Prolonged Endurance Exercise. Eur J Appl Physio l93, pp: 375–380.
